Cargando…

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?

Detalles Bibliográficos
Autores principales:	Patoulias, Dimitrios, Doumas, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641574/ https://www.ncbi.nlm.nih.gov/pubmed/32971587 http://dx.doi.org/10.3350/cmh.2020.0264

Ejemplares similares

Lean non-alcoholic fatty liver disease: do not forget diabetes
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2019)

Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Liraglutide for non-alcoholic fatty liver disease in children and adolescents: has a new era arrived?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Non-alcoholic fatty liver disease in patients with inflammatory bowel disease might boost cardiovascular disease burden
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease
por: Patoulias, Dimitrios, et al.
Publicado: (2018)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Endothelial dysfunction and COVID-19: What's the true impact on surrogate outcomes?
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerations
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Colchicine for the prevention of COVID-19 “hard” outcomes: All that glitters is not gold
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Sodium-glucose co-transporter-2 inhibitor mediated cardio-protection: does increase of hematocrit finally matter? Sub-analysis of a prospective, observational study
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711–7)
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Time to assess the effects of sodium–glucose co‐transporter‐2 inhibitors on the ‘forgotten' right ventricle?
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Leptospirosis as a Still Unknown and Underappreciated Disease
por: Turhan, Vedat, et al.
Publicado: (2012)

COVID-19 and ophthalmology: An underappreciated occupational hazard
por: Khatri, Anadi, et al.
Publicado: (2020)

Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials
por: Dimosiari, Athina, et al.
Publicado: (2022)

Menorrhagia: an underappreciated problem in pre-menopausal women with systemic lupus erythematosus
por: Wincup, C, et al.
Publicado: (2019)

Chloride Ion Is Not the Enemy
por: Sánchez Díaz, Jesús Salvador, et al.
Publicado: (2021)

The Invisible and Insidious Enemy
por: Chua, Marvin Wei Jie
Publicado: (2021)

The underappreciated wrong of AIgiarism - bypass plagiarism that risks propagation of erroneous and bias content
por: Tang, Bor Luen
Publicado: (2023)

Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Non-alcoholic fatty liver disease in lean individuals
por: Albhaisi, Somaya, et al.
Publicado: (2019)

Body Composition and Non-alcoholic Fatty Liver Disease
por: Abenavoli, Ludovico, et al.
Publicado: (2016)

miRNA-122: Can it unravel an alternative pathway in early diagnosis and prognosis of type 2 diabetes mellitus?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Canakinumab: can it untie the Gordian knot of cardiovascular disease in patients with familial Mediterranean fever?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Is there a distinct phenotype of diabetic patients who benefit from tofogliflozin?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Sodium glucose co-transporter 2 inhibitors mediated ketogenesis in patients with metabolic syndrome: clear benefit or anticipated fear?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Sexual dysfunction among women with systemic lupus erythematosus: might it reflect cardiovascular disease burden?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Serum chemerin in patients with rheumatoid arthritis: can it unravel the Chimera of concomitant type 2 diabetes?
por: Patoulias, Dimitrios Ioannis
Publicado: (2020)

Eyeing non-alcoholic fatty liver disease: The noninvasive way
por: Gude, Dilip
Publicado: (2011)

Silymarin: An option to treat non-alcoholic fatty liver disease
por: Colica, Carmela, et al.
Publicado: (2017)

Effect of COVID-19 on endothelial function evaluated with flow-mediated dilation: another prognostic marker? A meta-analysis of observational studies
por: Dimosiari, Athina, et al.
Publicado: (2022)

Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Noninvasive Imaging for the Evaluation of Non-Alcoholic Fatty Liver Disease Spectrum
por: Liu, Qianjiao, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease, diabetes medications and blood pressure
por: Ilias, Ioannis, et al.
Publicado: (2021)

Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
por: Jeong, Seogsong, et al.
Publicado: (2023)

Does a gluten-free diet determine the efficacy of sotagliflozin in patients with concomitant type 1 diabetes mellitus and celiac disease?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2018)

Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications
por: Kumar, Ramesh, et al.
Publicado: (2017)

Multipronged Approach to Assess Risk Factors for Non-alcoholic Fatty Liver Disease
por: Hidrus, Aizuddin, et al.
Publicado: (2022)

Hepatitis C virus infection and atherosclerotic cardiovascular disease: recent knowledge, further insights
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6q98g4s308ojsispimnt6f2r61